SCHEMBL26638882

SCHEMBL26638882

Cn1nc(-c2cscn2)cc1C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4A O75164 1/20 0.48
▸ KDM4B O94953 1/20 0.48
▸ KDM5C P41229 1/20 0.48
▸ KDM5B Q9UGL1 1/20 0.48
▸ KDM4E B2RXH2 4/20 0.45
▸ GRN P28799 1/20 0.45
▸ SORT1 Q99523 1/20 0.45
▸ CA12 O43570 1/20 0.40
▸ CA1 P00915 1/20 0.40
▸ CA2 P00918 1/20 0.40
▸ CA9 Q16790 1/20 0.40
▸ ECE1 P42892 1/20 0.40
▸ PTPN1 P18031 1/20 0.38
▸ TDP2 O95551 1/20 0.37
▸ PHGDH O43175 6/20 0.35
▸ PKM P14618 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ METAP1 P53582 2/20 0.33
▸ METAP2 P50579 1/20 0.33
▸ SLC16A3 O15427 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31412316 0.86 KDM4A (0.40) KDM4AKDM4BKDM5CKDM5BKDM4E
SCHEMBL26639015 0.84 CA12 (0.44) KDM4AKDM4BKDM5CKDM5BKDM4E
SCHEMBL26639153 0.81 KDM4A (0.44) KDM4AKDM4BKDM5CKDM5BKDM4E
SCHEMBL21233186 0.75 TDP2 (0.41) KDM4AKDM4BKDM5CKDM5BTDP2
SCHEMBL26638982 0.74 KDM4A (0.50) KDM4AKDM4BKDM5CKDM5BKDM4E
SCHEMBL26659258 0.72 KDM4E (0.49) KDM4AKDM5CKDM4EGRNSORT1
SCHEMBL19253450 0.72 GRN (0.56) KDM4EGRNSORT1CA12CA1
SCHEMBL6494629 0.72 KDM4E (0.51) KDM4AKDM5CKDM4EGRNSORT1
SCHEMBL26639095 0.72 KDM4E (0.42) KDM4EGRNSORT1CA12CA1
SCHEMBL22952453 0.71 TDP2 (0.36) KDM4AKDM4BKDM5CKDM5BTDP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12565494-B2 Inhibitors of human respiratory syncytial virus and metapneumovirus MERCK SHARP & DOHME LLC 2026-03-03 — — US disclosed
EP-4522604-A1 INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS Merck Sharp & Dohme LLC (US) 2025-03-19 — — EP disclosed
US-20250066323-A1 INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS MERCK SHARP & DOHME LLC (US) 2025-02-27 — — US disclosed
WO-2025038786-A1 INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS MERCK SHARP & DOHME LLC (US) 2025-02-20 — — WO disclosed
US-20230365551-A1 INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS MERCK SHARP & DOHME LLC (US) 2023-11-16 — — US disclosed
WO-2023220225-A1 INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS MERCK SHARP & DOHME LLC (US) 2023-11-16 — — WO disclosed
WO-2023220225-A1 INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS MERCK SHARP & DOHME LLC (US) 2023-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066323-A1 INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS METAP1, SARS1, RTF1 KDM4A 3943/4885KDM4B 3866/4885KDM5C 4616/4885
US-20230365551-A1 INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS NHERF1, ACE, METAP1 KDM4A 4244/4885KDM4B 4099/4885KDM5C 4575/4885
US-12565494-B2 Inhibitors of human respiratory syncytial virus and metapneumovirus NHERF1, ZC3HAV1, SARS1 KDM4A 3945/4885KDM4B 3834/4885KDM5C 3734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback